Overview

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

Status:
Completed

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time), safety, tolerability and antiviral activity to support dose recommendations of TMC114 with ritonavir and other antiretroviral agents in treatment-experienced, human immunodeficiency virus (HIV)-1 infected children and adolescents.

Phase:

Phase 2

Details

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Treatments:

Darunavir
Ritonavir